US FDA Emphasizes Timesavers In New eCopy Guidance
This article was originally published in Clinica
The US FDA's device center wants PDFs submitted through the system to be formatted properly to prevent unnecessary delays when reviewers work with them. With this aim in mind, on Dec. 3, the Center for Devices and Radiological Health released an updated guidance (PDF) for industry on its electronic copy (eCopy) program for medical device submissions based on recommendations from Booz Allen Hamilton as part of the contractor's ongoing independent review of FDA's procedures.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.